Home Journals Subjects About My LA Reviewers Authors News Submit
Username: Password:
.
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Perspectives in Medicinal Chemistry

Synopsis: An open access, peer reviewed electronic journal that covers drug design in the form of commentaries and reviews which do not require disclosure of proprietary information.


Indexing: Pubmed, Pubmed Central, Embase, Google Scholar, CAS, DOAJ, OAIster

Processing time: Decision in 2 weeks for 90% of papers.


Latest news:
Perspectives in Medicinal Chemistry is now indexed by Pubmed
RSS

NEWS

TWITTER
View factor:
Journal: 44683
Most read article: 2379
Editor in chief:
Yitzhak Tor
ISSN: 1177-391X


 
 
 


The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy

Authors: Xinjie Lu, Dong Lu, Mike Scully and Vijay Kakkar
Publication Date: 10 Apr 2008
Perspectives in Medicinal Chemistry 2008:2 57-73

Xinjie Lu1, Dong Lu2, Mike Scully1 and Vijay Kakkar1

1Thrombosis Research Institute, Manresa Road, London, SW3 6LR U.K. 2The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, U.K.

Abstract

Integrins have been reported to mediate cell survival, proliferation, differentiation, and migration programs. For this reason, the past few years have seen an increased interest in the implications of integrin receptors in cancer biology and tumor cell aggression. This review considers the potential role of integrins in cancer and also addresses why integrins are present attractive targets for drug design. It discusses of the several properties of the integrin-based chemotherapeutic agents currently under consideration clinically and provides an insight into cancer drug development using integrin as a target.

Categories: Pharmacology


Post comment




No comments yet...Be the first to comment.

Document tools

Download PDF
(500.06 KB)
View on Pubmed
Request Reprints
Export to Bibliography

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now


Recently published in this journal

Chaperone Therapy for Neuronopathic Lysosomal Diseases: Competitive Inhibitors as Chemical Chaperones for Enhancement of Mutant Enzyme Activities
- 26/May/2009

Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics
- 28/Apr/2009

Perspectives on Using Physcomitrella  Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
- 04/Mar/2009

Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- 09/May/2008

The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- 10/Apr/2008

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- 10/Apr/2008

Lunasin: A Novel Cancer Preventive Seed Peptide
- 25/Mar/2008

Effects of FK506 on Ca2+ Release Channels (Review)
- 18/Mar/2008

Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical Research
- 07/Mar/2008

Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
- 14/Feb/2008

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
- 10/Feb/2008

The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
- 18/Jan/2008

Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
- 11/Dec/2007

Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 11/Dec/2007

The pKa Distribution of Drugs: Application to Drug Discovery
- 17/Sep/2007

FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
- 06/Sep/2007

Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
- 26/Jun/2007



Related journals...